Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / American Depositary Shares, each representing 6 Ordinary Shares
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
153,890,194
-
Share change
-
-8,193,777
-
Total reported value
-
$150,022,429
-
Put/Call ratio
-
46%
-
Price per share
-
$0.97
-
Number of holders
-
75
-
Value change
-
-$8,879,193
-
Number of buys
-
24
-
Number of sells
-
33
Institutional Holders of ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) as of Q2 2024
As of 30 Jun 2024,
ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) was held by
75 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
153,890,194 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, EcoR1 Capital, LLC, NEA Management Company, LLC, BAILLIE GIFFORD & CO, Long Focus Capital Management, LLC, PFM Health Sciences, LP, MPM ASSET MANAGEMENT LLC, MPM BIOIMPACT LLC, BANK OF AMERICA CORP /DE/, and Rock Springs Capital Management LP.
This page lists
75
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.